Brief: Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat
17/06/2024 12:08
June 17 (Reuters) - Ovid Therapeutics Inc OVID.O :
* OVID THERAPEUTICS REPORTS ON TAKEDA’S ANNOUNCEMENT OF
PHASE 3
TOPLINE STUDY RESULTS FOR SOTICLESTAT
* OVID THERAPEUTICS INC: WILL PRIORITIZE AND PURSUE ITS
PROGRAMS
WITH FINANCIAL DISCIPLINE AND EXPECTS ITS CASH RUNWAY TO LAST
INTO FIRST HALF OF 2026
Source text for Eikon: ID:nGNX72Bfqq
Further company coverage: OVID.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ovid Therapeutics
See all newsOvid Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Ovid Therapeutics Q2 revenue beats estimates
Brief: Ovid Therapeutics Q2 EPS USD -0.08
Ovid Therapeutics Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Ovid Therapeutics Appoints Leading Physician-Scientist And Biotech Innovator Anna Greka, M.D., Ph.D., To Board Of Directors